- Home
- ACTU vs EPRX Comparison
ACTU vs EPRX Comparison
Compare ACTU & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- EPRX
- Stock Information
- Founded
- ACTU 2015
- EPRX 2011
- Country
- ACTU United States
- EPRX Canada
- Employees
- ACTU N/A
- EPRX N/A
- Industry
- ACTU
- EPRX
- Sector
- ACTU
- EPRX
- Exchange
- ACTU NYSE
- EPRX NYSE
- Market Cap
- ACTU 135.0M
- EPRX 137.7M
- IPO Year
- ACTU 2024
- EPRX N/A
- Fundamental
- Price
- ACTU $6.21
- EPRX $5.40
- Analyst Decision
- ACTU Strong Buy
- EPRX Strong Buy
- Analyst Count
- ACTU 1
- EPRX 1
- Target Price
- ACTU $20.00
- EPRX $12.00
- AVG Volume (30 Days)
- ACTU 152.8K
- EPRX 12.0K
- Earning Date
- ACTU 05-15-2025
- EPRX 08-07-2025
- Dividend Yield
- ACTU N/A
- EPRX N/A
- EPS Growth
- ACTU N/A
- EPRX N/A
- EPS
- ACTU N/A
- EPRX N/A
- Revenue
- ACTU N/A
- EPRX N/A
- Revenue This Year
- ACTU N/A
- EPRX N/A
- Revenue Next Year
- ACTU N/A
- EPRX N/A
- P/E Ratio
- ACTU N/A
- EPRX N/A
- Revenue Growth
- ACTU N/A
- EPRX N/A
- 52 Week Low
- ACTU $5.50
- EPRX $2.20
- 52 Week High
- ACTU $11.99
- EPRX $6.20
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- EPRX N/A
- Support Level
- ACTU N/A
- EPRX N/A
- Resistance Level
- ACTU N/A
- EPRX N/A
- Average True Range (ATR)
- ACTU 0.00
- EPRX 0.00
- MACD
- ACTU 0.00
- EPRX 0.00
- Stochastic Oscillator
- ACTU 0.00
- EPRX 0.00
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.